Drugs / LiveSpo X-secret
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06165354 | Dec 2023 → Dec 2024 | vaginitis | Anabio R&D | Completed | No outcome recorded |
| — | NCT05783856 | May 2020 → Mar 2023 | sexually transmitted disease | Anabio R&D | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LiveSpo X-secret | “Combination Product: LiveSpo X-secret” NCT06165354 ↗ |
| Modality | Other / unclassified | “vaginal-spraying probiotics containing Bacillus strains could be a safe and effective symptomatic treatment for STIs caused by viral, fungi, or bacterial pathogens” NCT05783856 ↗ |
| Route | Other | “vaginal-spraying probiotics” NCT05783856 ↗ |